You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 9, 2025

Claims for Patent: 9,814,708

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,814,708

Title:	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Abstract:	The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Inventor(s):	Sommer; Andreas (Carlsbad, CA), Zhang; Chengzhi (San Diego, CA), Carter; John (Vista, CA), Arthur; John (Vista, CA), Bradbury; Margaret (Vista, CA), Gant; Thomas (Carlsbad, CA), Shahbaz; Manouchehr (San Diego, CA)
Assignee:	Auspex Pharmaceuticals, Inc. (Frazer, PA)
Application Number:	15/044,655
Patent Claims:	1. An extended-release pharmaceutical formulation comprising 6 to 24 mg of d.sub.6-tetrabenazine and between about 5% and about 20% by weight, based on the weight of the formulation, of a poly(ethylene oxide) polymer, wherein upon administration to a subject: the formulation provides a reduction in dose relative to a formulation comprising non-deuterated tetrabenazine; and maintains at least the same AUC of the total combined amount of d.sub.6-.alpha.-dihydrotetrabenazine and d.sub.6-.beta.-dihydrotetrabenazine relative to .alpha.-dihydrotetrabenazine and .beta.-dihydrotetrabenazine of the formulation comprising non-deuterated tetrabenazine. 2. The extended-release pharmaceutical formulation of claim 1, wherein said d.sub.6-tetrabenazine is (+/-)-trans-d.sub.6-tetrabenazine. 3. The extended-release pharmaceutical formulation of claim 1, wherein the said reduction in dose is at least 30%. 4. The extended-release pharmaceutical formulation of claim 1, wherein said reduction in dose is at least 40%. 5. The extended-release pharmaceutical formulation of claim 1, wherein the formulation provides a reduction in C.sub.max of the total combined d.sub.6-.alpha.-dihydrotetrabenazine and d.sub.6-.beta.-dihydrotetrabenazine of at least 50% relative to the C.sub.max of .alpha.-dihydrotetrabenazine and .beta.-dihydrotetrabenazine following administration of a formulation comprising non-deuterated tetrabenazine to a subject. 6. The extended-release pharmaceutical formulation of claim 1, wherein the C.sub.max of the total combined d.sub.6-.alpha.-dihydrotetrabenazine and d.sub.6-.beta.-dihydrotetrabenazine is reduced by at least 50% relative to the C.sub.max of .alpha.-dihydrotetrabenazine and .beta.-dihydrotetrabenazine achieved upon administration of an immediate-release formulation of tetrabenazine that yields at least the same AUC of the total combined .alpha.-dihydrotetrabenazine and .beta.-dihydrotetrabenazine. 7. The extended-release pharmaceutical formulation of claim 6, wherein the C.sub.max is reduced by at least 60%. 8. The extended-release pharmaceutical formulation of claim 6, wherein the C.sub.max is reduced by at least 70%. 9. The extended-release pharmaceutical formulation of claim 6, wherein the C.sub.max is reduced by at least 75%. 10. The extended-release pharmaceutical formulation of claim 1, comprising 7.5 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 21.37.+-.6.78 ng/mL upon administration of the formulation to the subject. 11. The extended-release pharmaceutical formulation of claim 10, wherein the AUC.sub.inf of the total combined amount of d.sub.6-dihydrotetrabenazine is about 176.2.+-.69.3 hrng/mL mL upon administration of the formulation to the subject. 12. The extended-release pharmaceutical formulation of claim 10, wherein the AUC.sub.(0-12) of the total combined amount of d.sub.6-dihydrotetrabenazine is about 110.2.+-.32.1 hrng/mL upon administration of the formulation to the subject. 13. The extended-release pharmaceutical formulation of claim 10, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.17.+-.0.68 hr upon administration of the formulation to the subject. 14. The extended-release pharmaceutical formulation of claim 10, wherein the T.sub.half of the total combined amount of d.sub.6-dihydrotetrabenazine is about 7.18.+-.1.35 hr upon administration of the formulation to the subject. 15. The extended-release pharmaceutical formulation of claim 1, comprising 15 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 45.33.+-.8.31 ng/mL upon administration of the formulation to the subject. 16. The extended-release pharmaceutical formulation of claim 15, wherein the AUC.sub.inf of the total combined amount of d.sub.6-dihydrotetrabenazine is about 408.3.+-.147.2 hrng/mL upon administration of the formulation to the subject. 17. The extended-release pharmaceutical formulation of claim 15, wherein the AUC.sub.(0-12) of the total combined amount of d.sub.6-dihydrotetrabenazine is about 250.4.+-.64.0 hrng/mL upon administration of the formulation to the subject. 18. The extended-release pharmaceutical formulation of claim 15, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.21.+-.0.45 hr upon administration of the formulation to the subject. 19. The extended-release pharmaceutical formulation of claim 1, comprising 22.5 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 67.49.+-.16.72 ng/mL upon administration of the formulation to the subject. 20. The extended-release pharmaceutical formulation of claim 19, wherein the AUC.sub.inf of the total combined amount of d.sub.6-dihydrotetrabenazine is about 610.+-.291 hrng/mL upon administration of the formulation to the subject. 21. The extended-release pharmaceutical formulation of claim 19, wherein the AUC.sub.(0-12) of the total combined amount of d.sub.6-dihydrotetrabenazine is about 370.+-.123.7 hrng/mL upon administration of the formulation to the subject. 22. The extended-release pharmaceutical formulation of claim 19, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.79.+-.0.84 hr upon administration of the formulation to the subject. 23. The extended-release pharmaceutical formulation of claim 1, comprising 6 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 15.5.+-.3.5 ng/mL upon administration of the formulation to the subject with food. 24. The extended-release pharmaceutical formulation of claim 23, wherein the AUC.sub.inf of the total combined amount of d.sub.6-dihydrotetrabenazine is about 132.+-.47 hrng/mL upon administration of the formulation to the subject. 25. The extended-release pharmaceutical formulation of claim 23, wherein the AUC.sub.t of the total combined amount of d.sub.6-dihydrotetrabenazine is about 122.+-.46 hrng/mL upon administration of the formulation to the subject. 26. The extended-release pharmaceutical formulation of claim 23, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.74.+-.0.99 hr upon administration of the formulation to the subject. 27. The extended-release pharmaceutical formulation of claim 1, comprising 12 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 32.1.+-.8.1 ng/mL upon administration of the formulation to the subject with food. 28. The extended-release pharmaceutical formulation of claim 27, wherein the AUC.sub.ia of the total combined amount of d.sub.6-dihydrotetrabenazine is about 289.+-.115 hrng/mL upon administration of the formulation to the subject. 29. The extended-release pharmaceutical formulation of claim 27, wherein the AUC.sub.t of the total combined amount of d.sub.6-dihydrotetrabenazine is about 279.+-.114 hrng/mL upon administration of the formulation to the subject. 30. The extended-release pharmaceutical formulation of claim 27, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.90.+-.1.27 hr upon administration of the formulation to the subject. 31. The extended-release pharmaceutical formulation of claim 1, comprising 18 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 47.8.+-.12 ng/mL upon administration of the formulation to the subject with food. 32. The extended-release pharmaceutical formulation of claim 31, wherein the AUC.sub.inf of the total combined amount of d.sub.6-dihydrotetrabenazine is about 419.+-.165 hrng/mL upon administration of the formulation to the subject. 33. The extended-release pharmaceutical formulation of claim 31, wherein the AUC.sub.t of the total combined amount of d.sub.6-dihydrotetrabenazine is about 407.+-.163 hrng/mL upon administration of the formulation to the subject. 34. The extended-release pharmaceutical formulation of claim 31, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.63.+-.0.85 hr upon administration of the formulation to the subject. 35. The extended-release pharmaceutical formulation of claim 1, comprising 24 mg of d.sub.6-tetrabenazine, wherein the C.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 60.9.+-.13.8 ng/mL upon administration of the formulation to the subject with food. 36. The extended-release pharmaceutical formulation of claim 35, wherein the AUC.sub.inf of the total combined amount of d.sub.6-dihydrotetrabenazine is about 580.+-.229 hrng/mL upon administration of the formulation to the subject. 37. The extended-release pharmaceutical formulation of claim 35, wherein the AUC.sub.t of the total combined amount of d.sub.6-dihydrotetrabenazine is about 569.+-.225 hrng/mL upon administration of the formulation to the subject. 38. The extended-release pharmaceutical formulation of claim 35, wherein the T.sub.max of the total combined amount of d.sub.6-dihydrotetrabenazine is about 3.92.+-.1.19 hr upon administration of the formulation to the subject. 39. The extended-release pharmaceutical formulation of claim 1, comprising between about 10% and about 20% by weight, based on the weight of the formulation, of the poly(ethylene oxide) polymer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.